New Biocon Ph1 Oral Insulin Trial
A CT.gov record for a new Ph1 trial evaluating Biocon’s oral insulin Tregopil has been observed. Of note, the trial is being conducted by Profil in Mainz, Germany. Below, FENIX provides thoughts and insights into insulin Tregopil’s development including the challenges and commercial opportunity particularly around cold chain storage in underdeveloped geographies.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.